Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TT-816 Monotherapy and in Combination with Pembrolizumab in Advanced Cancers
NCT05525455Phase 2Terminated
- Sponsor
- Teon Therapeutics
- Start
- Aug 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of TT-816 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), ovarian cancer and 1 more (2 arms), sponsored by Teon Therapeutics. Primary endpoints: Incidence of adverse events (AEs) and serious adverse events (SAEs) at 3 years, Incidence and nature of dose-limiting toxicities (DLTs) up to 21 days and 4 more. Started Aug 2022; status: terminated.
02
Drugs
TT-816
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)ovarian cancerrenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05525455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05525455.